Nitrosamine contamination is a drug-quality problem in which compounds such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitroso-N-methyl-4-aminobutyric acid (NMBA) can appear as manufacturing or storage impurities. The modern scandal began when regulators found NDMA in valsartan in July 2018, then expanded to other blood-pressure drugs, heartburn medicines and several additional drug classes. Affected lots have been tested, held or recalled when concentrations exceeded the applicable acceptable intake.
For patients, the practical rule is straightforward: do not stop a prescription on your own. Check the exact product, strength, manufacturer and lot with a pharmacist or regulator, and arrange a clinically suitable replacement if that specific lot is affected. Nitrosamine limits are risk-management thresholds, not proof that every batch is contaminated or that exposure below a limit is absolutely harmless.
As an Amazon Associate I earn from qualifying purchases.
What the nitrosamine contamination scandal is
Nitrosamines are a family of chemical compounds that can occur in food, drinking water and medicines. Some, including NDMA and NDEA, are classified by the World Health Organization and the International Agency for Research on Cancer as probably carcinogenic to humans and part of the “cohort of concern” because they can damage DNA through mutagenic mechanisms.
Free tools Windows power users keep installed
One-click scans. No signup required.
The scandal concerns unintended impurities in medicines, not an ingredient deliberately added for therapeutic effect. A product can meet its specification for the active ingredient and still require investigation if a nitrosamine forms during synthesis, appears in a raw material, is introduced by a process change, or develops while the product is packaged or stored. The cause is product-specific; there is no single contamination pathway or universal test result for an entire drug class.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
FDA explains that long-term exposure above a nitrosamine’s acceptable daily intake (AI) may increase cancer risk. Taking a medicine at or below its AI every day for 70 years is not expected to increase cancer risk, although an AI is a conservative risk-management threshold rather than a guarantee of zero risk.
How the issue unfolded
| Date | Development | Why it mattered |
|---|---|---|
| July 2018 | Regulators became aware of NDMA in products containing valsartan, according to the WHO information note. | The finding triggered testing of other angiotensin-receptor blockers (ARBs) and their manufacturing routes. |
| 2018–2020 | Investigations identified additional nitrosamines, including NDEA, NDIPA, NEIPA and NMBA, in some sartan products and expanded to ranitidine, nizatidine, metformin, rifampin, rifapentine and other medicines. | Authorities moved from a single-product investigation to class-wide risk assessments and supply-chain reviews. |
| September 2024 | FDA issued revised final guidance, “Control of Nitrosamine Impurities in Human Drugs.” | The guidance sets out expectations for root-cause analysis, risk assessment, validated testing, confirmatory testing, controls, mitigation and alternative bioequivalence approaches. |
| Current oversight | FDA continues to evaluate products, while EMA’s Article 5(3) framework requires marketing-authorisation holders to assess risk, test products at risk and report confirmed findings promptly. | Recall and mitigation decisions remain specific to a product, lot, country and measured concentration. |
Which medicines and impurities were involved?
The presence of a nitrosamine in one manufacturer’s process or one lot does not mean that every batch, manufacturer or medicine with the same active ingredient is contaminated. The relevant comparison is always the measured impurity against the AI for that impurity and medicine.
| Medicine or class investigated | Impurities reported in the investigations | Important qualification |
|---|---|---|
| Valsartan and other sartans (ARBs) | NDMA, NDEA, NDIPA, NEIPA and NMBA | Findings varied by active-ingredient source, manufacturing route and lot; not every ARB batch was affected. |
| Ranitidine and nizatidine | NDMA | FDA laboratory testing found NDMA in tested active pharmaceutical ingredients and finished products; results do not establish that every historical or current lot has the same level. |
| Metformin | NDMA in some investigations | Testing and disposition were product- and lot-specific. |
| Rifampin and rifapentine | Nitrosamine impurities identified during broader investigations | Patients should rely on current national notices for the exact product and lot. |
| Other medicines | Potential small-molecule nitrosamines or nitrosamine drug substance-related impurities (NDSRIs) | FDA’s ongoing overview and later testing can add products as new evidence emerges. |
What happened with ranitidine
FDA’s laboratory page reports that NDMA was present in all ranitidine samples tested in that laboratory evaluation. FDA’s stated ranitidine reference is an acceptable daily intake of 0.096 micrograms (96 nanograms) per day, corresponding to 0.32 parts per million (ppm), on the agency page current in 2026. That figure applies to the ranitidine assessment; acceptable intakes differ among nitrosamines and medicines.
Recommended Free Tools
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Ranitidine illustrates why a finding needs context. Investigators considered both impurity present in supplied active ingredient and the possibility that NDMA could increase under certain storage conditions. A result for a tested sample cannot be generalized to every product in every country without lot-level evidence.
Why nitrosamines can form in medicines
FDA separates conventional, small-molecule nitrosamine impurities from NDSRIs. Small-molecule impurities are not structurally part of the active ingredient and may arise from reagents, solvents, catalysts, contaminated raw materials or recycled processing streams. NDSRIs share structural features with the active pharmaceutical ingredient and are often unique to that molecule.
Investigators examine the entire product life cycle:
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
- Manufacturing chemistry: Nitrite sources can react with amines under particular conditions, creating a nitrosamine if the process is not adequately controlled.
- Raw materials and intermediates: An upstream supplier may introduce a nitrosating agent or an already-formed impurity.
- Process changes: A change in solvent, catalyst, temperature, recovery step, equipment or supplier can alter impurity formation even when the finished formulation appears unchanged.
- Packaging and storage: Container materials, excipients, humidity, heat and time can affect whether an impurity forms or increases after manufacture.
- Drug-specific reactions: The structure of an API or its degradants can create an NDSRI pathway that does not exist for another medicine.
Because these pathways differ, a regulator may require a manufacturer to change a reaction, qualify a new raw-material source, alter packaging, set a tighter process control or add routine release testing rather than withdraw an entire class of medicines.
How acceptable-intake limits work
An acceptable intake converts toxicology into a daily exposure target, expressed as a mass per day, a concentration such as ppm, or both. Regulators compare the expected patient exposure with that target and consider dose, duration, maximum daily use and the medicine’s clinical importance. The calculation is specific to the nitrosamine and product; one compound’s limit cannot be transferred automatically to another.
When compound-specific carcinogenicity data are limited, EMA describes three principal approaches:
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
- Carcinogenic potency categorisation approach (CPCA): Structural features place a nitrosamine in a potency category from which an AI can be derived.
- Read-across and structure–activity assessment: Data from chemically related compounds inform a scientifically justified limit.
- Enhanced Ames testing or in-vivo data: Additional genotoxicity or animal evidence can refine the estimate when standard information is insufficient.
These methods are deliberately conservative. Staying below an AI means the modeled lifetime cancer risk is considered acceptably low under the regulator’s assumptions; it does not certify a batch as “risk-free,” and it does not authorize a patient to exceed the labeled dose.
How regulators and manufacturers detect and control impurities
FDA’s 2024 guidance calls for a documented risk assessment, validated analytical methods, confirmatory testing, investigation of the root cause, preventive controls and mitigation. A typical sequence is:
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstall- Screen the process and molecule: Review the API structure, reagents, solvents, suppliers, excipients, packaging and storage conditions for plausible nitrosation pathways.
- Test with a fit-for-purpose method: FDA’s methods work includes liquid chromatography–high-resolution mass spectrometry (LC-HRMS), liquid chromatography–tandem mass spectrometry (LC-MS/MS) and other methods for ARBs, ranitidine, metformin, varenicline, propranolol and bumetanide.
- Confirm unexpected results: Laboratories verify identity and concentration with an orthogonal or confirmatory procedure before a regulatory decision.
- Compare exposure with the applicable AI: The calculation uses the highest labeled daily dose and the measured impurity, not simply whether a signal was detected.
- Implement mitigation: Manufacturers may alter chemistry, suppliers, specifications, packaging, storage instructions or batch-release testing.
- Notify authorities and monitor: Confirmed findings are reported, affected distribution is held or recalled when warranted, and follow-up batches are tested to show that controls work.
EMA’s Article 5(3) framework similarly places the initial risk assessment and testing obligation on marketing-authorisation holders and requires prompt reporting of confirmed findings. This makes contamination control an ongoing quality-system responsibility rather than a one-time recall exercise.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
What patients should do if a medicine may be affected
- Keep taking the medicine unless a clinician tells you otherwise. FDA’s patient advice is that people taking medicines with potential nitrosamine impurities should not stop treatment on their own. Abruptly stopping an antihypertensive, diabetes medicine or other chronic therapy can create a more immediate danger than the modeled impurity risk.
- Identify the exact product. Record the active ingredient, strength, dosage form, manufacturer, pharmacy, prescription number and lot or batch number. A recall may cover only selected lots, strengths or countries.
- Ask a pharmacist or prescriber to check current notices. They can compare your lot with the latest FDA, EMA or national-regulator communication and determine whether an alternative is clinically appropriate.
- Do not substitute by dose or appearance. Different products with the same active ingredient may have different release characteristics, excipients, manufacturing sources or impurity results. Use only the replacement and dose prescribed for you.
- Follow recall instructions. If a lot is recalled, the pharmacy or regulator will explain whether to return it, obtain a replacement, continue temporarily while supply is arranged, or dispose of it through an approved medicine take-back route.
- Report problems through the normal pharmacovigilance channel. Report suspected adverse effects and provide the product and lot details; this helps authorities connect quality signals with specific batches.
Seek urgent medical help for symptoms of an uncontrolled underlying condition, an overdose or an allergic reaction. Nitrosamine exposure itself usually does not produce a distinctive immediate symptom, so routine medical advice should focus on maintaining treatment and checking the product identity.
Are nitrosamines still found in medicines?
Yes, the possibility remains under active surveillance, but “still found” does not mean that all medicines or all batches contain them above a limit. New formulations, suppliers and manufacturing changes can create different risk profiles, while improved controls can reduce or eliminate a previously identified pathway. FDA continues to evaluate products, and the 2024 guidance gives manufacturers a framework for prospective prevention as well as retrospective investigation.
Regulatory status also differs by geography. A product held or recalled in one country may have a different manufacturer, formulation, lot distribution or legal status elsewhere. Current information must therefore be checked against the national regulator, product name, strength and lot rather than inferred from a headline about the same active ingredient.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
How to read a recall or safety notice
A useful notice should answer six questions. If one is missing, ask the pharmacy or regulator for clarification:
- Which impurity? NDMA, NDEA, NMBA or another identified N-nitrosamine.
- Which medicine and source? The API, finished product, manufacturer and manufacturing site.
- Which lots and markets? Lot numbers, expiration dates, strengths, dosage forms and countries supplied.
- What level was measured? The result and the applicable AI, with units and testing conditions.
- What action was taken? Distribution hold, recall, process change, added testing or continued supply with controls.
- What should patients do? Continue, switch, return or dispose—and who will arrange replacement treatment.
This checklist prevents two common errors: assuming a positive result applies to every batch, and treating a recall notice as permission to stop an essential medicine without a replacement plan.
Bottom line for patients and clinicians
The nitrosamine saga exposed preventable weaknesses in pharmaceutical supply chains, but it also produced stronger testing and risk-management requirements. NDMA and related compounds are serious hazards at sustained exposures above their acceptable intakes; the response is lot-specific investigation, validated measurement and controlled substitution—not panic or unsupervised discontinuation. For any current concern, identify the exact product and lot and obtain advice from a pharmacist, prescriber and the regulator serving your country.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
